| Drug treatment-induced downregulation of antiphospholipid antibodies in PAPS. | |
| | |
MedLine Citation:
|
PMID: 19693642 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Although low-dose methotrexate (MTX) has been used to treat several autoimmune diseases like lupus erythematosus, rheumatoid arthritis, etc., it has not yet been used to treat patients with primary antiphospholipid syndrome (PAPS). Parallel to clinical follow-up of female patient with a severe form of PAPS, antiphospholipid antibodies (aPL), blood coagulation, and hematological parameters in the peripheral blood have been monitored. MTX improved ulcers, livedo reticularis, decreased aPL titers, increased platelet counts, and improved blood coagulation parameters (e.g., factor VIII) and was well tolerated. Low-dose MTX was safe and effective in the presented case with PAPS. The clinical benefit may be due to the downregulation of increased aPL titers and amelioration of disturbed coagulation parameters. |
| | |
Authors:
|
Ingrid Boehm |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-08-20 |
Journal Detail:
|
Title: Clinical rheumatology Volume: 28 ISSN: 1434-9949 ISO Abbreviation: Clin. Rheumatol. Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-09-25 Completed Date: 2009-12-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8211469 Medline TA: Clin Rheumatol Country: Germany |
Other Details:
|
Languages: eng Pagination: 1347-8 Citation Subset: IM |
Affiliation:
|
Department of Radiology, University of Bonn, Sigmund-Freud Strasse 25, Bonn 53105, Germany. i.boehm@uni-bonn.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Antiphospholipid
/
drug effects*,
immunology Antiphospholipid Syndrome / complications, drug therapy*, immunology Blood Coagulation / drug effects Blood Platelets / drug effects Dose-Response Relationship, Drug Female Humans Immunosuppressive Agents / administration & dosage, therapeutic use* Injections, Intravenous Methotrexate / administration & dosage, therapeutic use* Middle Aged Partial Thromboplastin Time Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Antiphospholipid; 0/Immunosuppressive Agents; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab.
Next Document: No association of the TLR2 gene Arg753Gln polymorphism with rheumatic heart disease and Beh??et's di...